TheranosticTrials.org

Clinical Trial · NCT06548529

HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

Overview

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

ClinicalTrials.gov

NCT06548529

Drug / Compound

HER2 Affibody

Isotope(s):
Target(s):
  • HER2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA

Eligibility

Inclusion

  • Life expectancy \> 3 months
  • was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane;
  • Is unresectable or metastatic;
  • Patients with HER2 positive or suspicious positive tumors;
  • Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
  • Receives anti-HER2 ADC treatment

Exclusion

  • Significant hepatic or renal dysfunction;
  • Cannot keep their states for half an hour;
  • Refused to join the clinical research;
  • Is pregnant or ready to pregnant;
  • Suffering from claustrophobia or other mental disorders;
  • Any other situation that researchers considered it unsuitable to participate in the trial.